MolecularHealth Hires Medical Director for U.S. Next-Gen Sequencing Lab
Gabriel Bien-Willner, M.D., Ph.D., joins MolecularHealth as the new medical director of its U.S. laboratory
THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth announced today the appointment of Gabriel Bien-Willner, M.D., Ph.D., as medical director of its CLIA-certified next-generation sequencing lab in The Woodlands, Texas. Since the launch of TreatmentMAP™, the company’s cancer treatment decision support offering, the number of incoming test requests have continued to increase. Dr. Bien-Willner will report to Chief Medical Officer Dr. Shelly Gunn and manage the day-to-day clinical duties of the laboratory.
“Dr. Bien-Willner is a classically-trained molecular pathologist with deep next-generation sequencing expertise who will be instrumental to the success of our U.S. lab and our ability to accurately and quickly process patient samples.”
“We are very pleased that Dr. Bien-Willner will be joining our growing team at MolecularHealth. He has a long history of providing knowledgeable insight into the molecular basis of disease in cancer patients,” said Dr. Gunn. “Dr. Bien-Willner is a classically-trained molecular pathologist with deep next-generation sequencing expertise who will be instrumental to the success of our U.S. lab and our ability to accurately and quickly process patient samples.”
Dr. Bien-Willner comes to MolecularHealth with dual-board certifications in anatomic pathology and molecular genetic pathology. He has expertise in genetics and genomics, next-generation sequencing technology and pipeline design. Prior to joining Molecular Health, he served as a faculty member in the Department of Pathology and Immunology at Washington University in St. Louis, where he conducted research in cancer biomarker discovery and the development of novel genomic technologies. His research has earned him several prestigious awards, including the Stowell-Orbison Award, the Association for Molecular Pathology Young Investigator Award, and has been designated a College of American Pathologist Scholar.
MolecularHealth’s TreatmentMAP was commercially launched in the United States and Europe in April. Using a proprietary analytics engine to combine precision medicine with advanced data analysis, the offering guides physicians to the safest and most effective cancer treatment options for their patients. TreatmentMAP is accessible to all patients diagnosed with solid tumor cancer, regardless of where they live.
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.